Trial Profile
A Single-Arm, Pilot Study Evaluating the Short Term Effect of Dapagliflozin as Add on to Standard Therapy in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus (T2DM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2017
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Decompensated heart failure; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- 28 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.